This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Resumen de acción JNCE
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Competidores de Jounce Therapeutics, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.88 |
| 52 Week High | US$5.49 |
| 52 Week Low | US$0.58 |
| Beta | 0.75 |
| 1 Month Change | -0.53% |
| 3 Month Change | 55.37% |
| 1 Year Change | -65.76% |
| 3 Year Change | -60.34% |
| 5 Year Change | -88.80% |
| Change since IPO | -89.10% |
Noticias y actualizaciones recientes
Recent updates
We're A Little Worried About Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Rate
Jan 04
Here's Why We're Watching Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Situation
Sep 20Here's Why We're A Bit Worried About Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Situation
Jun 16We Think Jounce Therapeutics (NASDAQ:JNCE) Can Easily Afford To Drive Business Growth
Feb 23Jounce Therapeutics: A Favorable Risk-Reward Ahead Of Critical 2022 Catalysts
Dec 16News Flash: Analysts Just Made A Dazzling Upgrade To Their Jounce Therapeutics, Inc. (NASDAQ:JNCE) Forecasts
Aug 07Jounce Therapeutics: An Under The Radar And Undervalued Biotech
Jul 13Need To Know: Analysts Are Much More Bullish On Jounce Therapeutics, Inc. (NASDAQ:JNCE) Revenues
Jun 16Shareholders May Not Be So Generous With Jounce Therapeutics, Inc.'s (NASDAQ:JNCE) CEO Compensation And Here's Why
Jun 12Jounce Therapeutics EPS beats by $0.01, misses on revenue
May 04We're Hopeful That Jounce Therapeutics (NASDAQ:JNCE) Will Use Its Cash Wisely
May 03Jounce Therapeutics (NASDAQ:JNCE) Shareholders Have Enjoyed An Impressive 163% Share Price Gain
Mar 02News Flash: Analysts Just Made A Sizeable Upgrade To Their Jounce Therapeutics, Inc. (NASDAQ:JNCE) Forecasts
Mar 02Enrollment underway in Jounce Therapeutics' early-stage JTX-8064 study in solid tumors
Jan 13Have Insiders Sold Jounce Therapeutics, Inc. (NASDAQ:JNCE) Shares Recently?
Jan 13
Jounce Therapeutics: A Potential Roller Coaster
Dec 31A Look At Jounce Therapeutics' (NASDAQ:JNCE) CEO Remuneration
Dec 15Rentabilidad de los accionistas
| JNCE | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | -2.6% | -2.5% | -3.2% |
| 1Y | -65.8% | -3.7% | 19.3% |
Rentabilidad vs. Industria: JNCE underperformed the US Biotechs industry which returned 16.2% over the past year.
Rentabilidad vs. Mercado: JNCE underperformed the US Market which returned -1.4% over the past year.
Volatilidad de los precios
| JNCE volatility | |
|---|---|
| JNCE Average Weekly Movement | 15.4% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: JNCE's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: JNCE's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2012 | 141 | n/a | jouncetx.com |
Resumen de fundamentos de Jounce Therapeutics, Inc.
| Estadísticas fundamentales de JNCE | |
|---|---|
| Capitalización bursátil | US$98.96m |
| Beneficios(TTM) | -US$50.92m |
| Ingresos (TTM) | US$82.00m |
1.2x
Ratio precio-ventas (PS)-1.9x
Ratio precio-beneficio (PE)¿Está JNCE sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de JNCE | |
|---|---|
| Ingresos | US$82.00m |
| Coste de los ingresos | US$54.80m |
| Beneficio bruto | US$27.20m |
| Otros gastos | US$78.12m |
| Beneficios | -US$50.92m |
Últimos beneficios comunicados
Dec 31, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.97 |
| Margen bruto | 33.17% |
| Margen de beneficio neto | -62.10% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado JNCE a largo plazo?
Ver rendimiento hist órico y comparativa